News

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process.

Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and other commodities in highly energetically favorable (high yield, high purity) production. Allozymes is optimizing key enzymes in the pathway to meet large-scale production specifications. The collaboration includes Allozymes’ cutting edge microfluidics-based protein engineering platform to achieve what was previously thought impossible: analyzing up to 20 million enzyme variants a day, delivering superior success rates, and dramatically reducing development timelines for novel enzymes.

“Optimizing enzymes for industrial-scale production requires precision, speed, and innovation, and our collaboration with Bonumose exemplifies this,” said Akbar Vahidi, Chief Technology Officer of Allozymes. “By leveraging our microfluidics-based protein engineering platform, we have been able to rapidly enhance key enzymes, significantly improving the process efficiency and scalability. The early results are promising, and we are confident that this partnership will unlock new possibilities in sustainable and cost-effective ingredient production.”

Dr. Daniel Wichelecki, Bonumose’s Chief Scientific Officer and Co-Founder, states, “Our mission is to produce healthy food and supplement ingredients in a low-cost, scalable production process. Our development collaborator Allozymes has shown promising results in the initial phases of our collaboration. We are on track and confident to meet our developmental objectives.”

The companies are pleased with the important milestone in both companies’ agenda of leveraging the use of enzymes to accelerate timelines and meet ambitious targets for producing beneficial ingredients to meet global needs for healthy food, dietary supplements, and other important categories.

“Our goal is to drive the future of sustainable food ingredient production through enzyme innovation,” said Akbar Vahidi. “Our collaboration with Bonumose is a critical part of this mission and we aim to demonstrate a successful model on how Allozymes enables innovation in the food ingredient market. With our unique platform, we are confident that we’ll continue to reduce development timelines and enhance performance, setting a new benchmark in the industry.”

 

Read more here.

Recent News

07/30/2026

Governor Spanberger Announces $2.4 Million in Grants for Virginia’s Biomedical Innovation Ecosystem

Governor Abigail Spanberger today announced a $2.4 million investment in Virginia’s life sciences ecosystem through Virginia Catalyst’s highly competitive grant program. Virginia Catalyst was founded in 2013 as Virginia’s research consortium through the efforts of the Virginia General Assembly and five of Virginia’s premiere research institutions. These non-dilutive grants — funding that does not require

07/29/2026

Slone Partners Names Sona Stroud and Kim Wilson as Senior Partners

Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, today announced the appointments of Sona Stroud and Kim Wilson as Senior Partners. Stroud has been promoted to the role following nearly 15 years with the firm, while Wilson returns to the organization, further strengthening its leadership team with nearly 17 years

07/28/2026

NanOptical Biomedical Commercializes Cancer Imaging Technology

NanOptical Biomedical Inc., a biotechnology company working on next-generation contrast agents for photoacoustic imaging, has started operations at the Endeavor incubator in Innovation Park, Manassas. The company will manufacture SonoVanta™, a patent-pending contrast agent that improves the precision of cancer margin imaging, supporting more accurate biopsies and tumor removal. SonoVanta™ originated from research conducted at